Latest news
{{'2026-11-13T11:00:00Z' | dateFormatFilter}}
Novo submits etavopivat, an investigational once-daily therapy for adolescents and adults living with sickle cell disease, to the FDA and EMA for approval
{{'2026-11-11T09:30:00Z' | dateFormatFilter}}
Novo commits USD 200 million over 10 years to support the World Diabetes Foundation to strengthen diabetes prevention and care
{{'2026-11-08T18:45:00Z' | dateFormatFilter}}
Novo post hoc analysis finds Wegovy 2.4 mg was associated with improvements in liver markers in adults with MASH with liver scarring and a BMI less than 27 kg/m2, presented at The Liver Meeting® (AASLD) 2026
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}
